Combinatorial versus individual gene pharmacogenomic testing in mental health: A perspective on context and implications on clinical utility

Yale Journal of Biology and Medicine

Volumn 88, Issue 4, 2015, Pages 375-382

  Winner, Joel G ^a   Dechairo, Bryan ^a  

^a Assurex Health   (United States)

Author keywords

Clinical utility; Clinical validity; Combinatorial; Economic outcomes; Mental health; Pharmacogenomics

Indexed keywords

ALLELE; GENETIC PREDISPOSITION; HUMAN; HUMAN EXPERIMENT; MENTAL HEALTH; PHARMACOGENOMICS; PUBLICATION; VALIDITY; COMPARATIVE STUDY; GENE; GENETIC SCREENING; GENETICS; MENTAL DISEASE; PHARMACOGENETICS; PROCEDURES;

GENES; GENETIC TESTING; HUMANS; MENTAL DISORDERS; PHARMACOGENETICS;

EID: 84948656850     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet. 2001;2:9-39.
2. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and vKORC1 Genotypes and Warfarin Dosing. Clin Pharmacol Ther. 2011;90(4):625-9.
3. Nebert DW, Bingham E. Pharmacogenomics: Out of the lab and into the community. Trends Biotechnol. 2001;19(12):519-23.
4. Friedman RA. On the Horizon, Personalized Depression Drugs. The New York Times. 2007 June 19.
5. Phillips K, van Bebber SL. Measuring the value of pharmacogenomics. Nat Rev Drug Discov. 2005;4(6):500-9.
6. Raimundo S1, Toscano C, Klein K, Fischer J, Griese EU, Eichelbaum M, et al. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther. 2004;76(2):128-38.
7. Pharmacogenetics. LapCorp [Internet]. [cited 2015 Sept 11]. Available from: https://www.labcorp.com/wps/portal/!ut/p/c1/04_SB8K8xLLM9MSSzPy8xBz9CP0os_hQv5NgQ09LYwMDS38nAyMv8zAjC6cgI_cAA6B8pFl8oIWZX6CRn5GBha-Rm4GRsZmTgamzq6GBgQeB3X4e-bmp-gW5eeUAMTMnvQ!!/dl2/d1/L0lDU0lKSWdrbUe-hIS9JRFJBQUlpQ2dBek15cXchL1lCSkoxTkexTkk1MC01RncvN19vRTRTMUk5MzAwRjcyMDJKTkR-WRUZFMjAwNy9MX19fXzQ!/?WCM_PORTLeT=PC_7_Ue4S1I9300F7202JNDveFe2007_WCM&WCM_GLOBAL_CONTeXT=/wps/wcm/connect/labcorp+content/LabCorp/Provider/Resources/Services/Pharmacogenetics
8. Tests. Genelex [Internet]. [cited 2015 Sept 11]. Available from: http://genelex.com/pharmacogenetic-tests/
9. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University Department of Medicine [Internet]. 2007. Available from: http://medicine.iupui.edu/clinpharm/DDIs/
10. Winner JG, Goebert D, Matsu C, Mrazek DA. Training in psychiatric genomics during residency: a new challenge. Acad Psychiatry. 2010;34(2):115-8.
11. Hicks J, Bishop J, Sangkuhl K, Müller D, Ji Y, Leckband S, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015;98(2):127-34.
12. Tsai M-H, Lin K-M, Hsiao M-C, Shen WW, Lu M-L, Tang H-S, et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics. 2010;11(4):537-46.
13. Guidance for industry. Drug interaction studies study design, data analysis, implications for dosing, and labeling recommendations. Food and Drug Administration [Internet]. 2012. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf
14. Steimer W, Zöpf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, et al. Amitriptyline or not, that is the question: Pharmacogenetic testing of CYP2D6 and CYP2C19 identi- fies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem. 2005;51(2):376-85.
15. Jornil J, Jensen KG, Larsen F, Linnet K. Risk assessment of accidental nortriptyline poisoning: The importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator. Eur J Pharm Sci. 2011;44(3):265-72.
16. Haufroid V, Hantson P. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants. Clin Toxicol (Phila). 2015;53(6):501-10.
17. The Human Cytochrome P450 (CYP) Allele Nomenclature Committee. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Internet] [cited 2015 Sept 11]. Available from: http://www.cypalleles.ki.se/.
18. Mrazek DA. Psychiatric Pharmacogenomics. New York: Oxford University Press; 2010.
19. Müller DJ, Kekin I, Kao ACC, Brandl EJ. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. Int Rev Psychiatry. 2013;25(5):554-71.
20. Evaluation of Genomic Applications in Practice and Prevention (eGAPP) Working Group. Recommendations from 382 Winner and Dechairo: Combinatorial pharmacogenomic testing the eGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med. 2007;9(12):819-25.
21. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch eD, ellingrod vL, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants. Clin Pharmacol Ther. 2013;93(5):402-8.
22. Local Coverage Determination (LCD): CYP2C19, CYP2D6, CYP2C9, and vKORC1 Genetic Testing (L35327). Centers for Medicare & Medicaid Services [Internet] [cited 2015 Sept 11]. Available from: http://www.mediquant.com/policy/L35327_20150828.pdf.
23. Chou WH, Yan FX, de Leon J, Barnhill J, Rogers T, Cronin M, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol. 2000;20(2):246-51.
24. Herbild L, Andersen SE, Werge T, Rasmussen HB, Jürgens G. Does Pharmacogenetic Testing for CYP450 2D6 and 2C19 Among Patients with Diagnoses within the Schizophrenic Spectrum Reduce Treatment Costs? Basic Clin Pharmacol Toxicol. 2013;113(4):266-72.
25. Ruano G, Szarek BL, villagra D, Gorowski K, Kocherla M, Seip RL, et al. Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder. Biomark Med. 2013;7(3):429-39.
26. Fagerness J, Fonesca E, Hess GP, et al. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am J Manag Care. 2014;20(5):e146-56.
27. Serretti A, Olgiati P, Bajo E, Bigelli M, DE Ronchi D. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World J Biol Psychiatry. 2011;12(7):501-15.
28. Olgiati P, Bajo E, Bigelli M, DE Ronchi D, Serretti A. Should pharmacogenetics be incorporated in major depression treatment? economic evaluation in high and middle-income european countries. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36(1):147-54.
29. Chua EW, Foulds J, Miller AL, Kennedy MA. Novel CYP2D6 and CYP2C19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetine. Pharmacogenet Genomics. 2013;23(9):494-7.
30. Stephan P, Sirot E, Mueller B, eap C, Baumann P. Adverse Drug Reactions Following Nonresponse in a Depressed Patient with CYP2D6 Deficiency and Low CYP 3A4/5 Activity. Pharmacopsychiatry. 2006;39(4):150-2.
31. Harris E, Eng HY, Kowatch R, Delgado SV, Saldaña SN. Disinhibition as a Side effect of Treatment with Fluvoxamine in Pediatric Patients with Obsessive-Compulsive Disorder. J Child Adolesc Psychopharmacol. 2010;20(4):347-53.
32. Jornil J, Nielsen TS, Rosendal I, Ahlner J, Zackrisson AL, Boel LWT, et al. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. Forensic Sci Int. 2013;226(1-3):e26-31.
33. Neukamm MA, Vogt S, Hermanns-Clausen M, Naue J, Thierauf A, Auwärter v. Fatal doxepin intoxication - Suicide or slow gradual intoxication? Forensic Sci Int. 2013;227(1-3):82-4.
34. Emoto C, Fukuda T, Venkatasubramanian R, Vinks AA. The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically based pharmacokinetics model. Br J Clin Pharmacol. 2015. epub ahead of print.
35. McAlpine DE, Biernacka JM, Mrazek DA, OʼKane DJ, Stevens SR, Langman LJ, et al. Effect of Cytochrome P450 enzyme Polymorphisms on Pharmacokinetics of venlafaxine. Ther Drug Monit. 2011;33(1):14-20.
36. Suzuki Y, Sawamura K, Someya T. Polymorphisms in the 5 hydroxytryptamine 2A receptor and cytochrome P4502D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients. Neuropsychopharmacology. 2006;31(4):825-31.
37. Hall-Flavin DK, Winner JG, Allen JD, et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry. 2012;2:e172.
38. Hall-Flavin DK, Winner JG, Allen JD, Carhart JM, Proctor B, Snyder KA, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics. 2013;23(10):535-48.
39. Winner JG, Carhart JM, Altar CA, Allen JD, Dechairo BM. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov Med. 2013;16(89):219-27.
40. Altar CA, Carhart JM, Allen JD, Hall-Flavin DK, Dechairo BM, Winner JG. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharmacogenomics J. 2015;15(5):443-51.
41. FDA Clears Genetic Lab Test for Warfarin Sensitivity. US Food and Drug Administration [Internet]. 2007. Available from: http://www.fda.gov/newsevents/newsroom/pressan-nouncements/2007/ucm108984.htm.
42. WarfarinDosing.org [Internet] St. Louis: Washington University. [cited 2015 Sept 14]. Available from: http://warfarindosing.org/Source/Home.aspx.
43. Winner J, Allen JD, Altar CA, Spahic-Mihajlovic A. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry. 2013;3:e242.
44. Winner JG, Carhart JM, Altar CA, Goldfarb S, Allen JD, Lavezzari G, et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a one year prospective evaluation. Curr Med Res Opin. 2015;18;1-30.
45. CGS Administrators. MoPath: GeneSight Assay for Refractory Depression (L35437). MediQuant.com [Internet]. Available from: http://www.mediquant.com/policy/L35437_20141024.pdf.
46. Tansey KE, Guipponi M, Hu X, Domenici E, Lewis G, Malafosse A, et al. Contribution of Common Genetic variants to Antidepressant Response. Biol Psychiatry. 2013;73(7):679-82.